Disease relevance of Butyrylyperazine

• Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia [1].

Psychiatry related information on Butyrylyperazine

• Initially, this dose of butaperazine inhibited stereotyped behavior in response to subcutaneous administration of apomorphine, but this effect was reversed at 12 hours [2].

High impact information on Butyrylyperazine

• Morning prolactin and clinical symptomatology were measured in 15 schizophrenic patients before neuroleptic therapy, and after three and six weeks of high-dose butaperazine or loxapine treatment [3].
• Dystonias appeared on falling drug concentrations, more than one half-life after plasma and red blood cell (RBC) peak butaperazine concentrations [4].
• Red blood cell butaperazine kinetics differentiated better than did plasma butaperazine levels those subjects in whom dystonias would develop from those in whom they did not [4].
• Butaperazine pharmacokinetics. Effect of dosage regimen on steady state blood levels [5].
• In addition, evidence indicated possible enzyme induction by butaperazine in one patient [5].

Analytical, diagnostic and therapeutic context of Butyrylyperazine

• Determination of butaperazine in plasma and red blood cells by fluorometry [6].
• Determination of butaperazine in biological fluids by gas chromatography using nitrogen specific detection system [7].
• It was also extended to measure butaperazine levels in rat red blood cells, plasma, liver, and brain after intraperitoneal injection (15 mg/kg) [7].

References